

Ruben Queiro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6423968/publications.pdf>

Version: 2024-02-01

158
papers

3,081
citations

159585
30
h-index

214800
47
g-index

174
all docs

174
docs citations

174
times ranked

2930
citing authors

#	ARTICLE	IF	CITATIONS
1	A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 68-70.	0.9	125
2	Power Doppler Ultrasonography Assessment of Entheses in Spondyloarthropathies: Response to Therapy of Enthesal Abnormalities. <i>Journal of Rheumatology</i> , 2010, 37, 2110-2117.	2.0	125
3	Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2013, 169, 783-793.	1.5	124
4	Age at disease onset: a key factor for understanding psoriatic disease. <i>Rheumatology</i> , 2014, 53, 1178-1185.	1.9	103
5	Subclinical Sacroiliitis in Inflammatory Bowel Disease: A Clinical and Follow-up Study. <i>Clinical Rheumatology</i> , 2000, 19, 445-449.	2.2	86
6	Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. <i>Human Molecular Genetics</i> , 2012, 21, 4549-4557.	2.9	79
7	Clinical features and predictive factors in psoriatic arthritis-related uveitis. <i>Seminars in Arthritis and Rheumatism</i> , 2002, 31, 264-270.	3.4	78
8	Psoriatic spondyloarthropathy: A comparative study between HLA-B27 positive and HLA-B27 negative disease. <i>Seminars in Arthritis and Rheumatism</i> , 2002, 31, 413-418.	3.4	78
9	Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus. <i>Journal of Dermatological Science</i> , 2014, 75, 167-172.	1.9	73
10	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766.	3.4	73
11	Clinically Asymptomatic Axial Disease in Psoriatic Spondyloarthropathy. A Retrospective Study. <i>Clinical Rheumatology</i> , 2002, 21, 10-13.	2.2	70
12	Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. <i>Arthritis Research and Therapy</i> , 2017, 19, 72.	3.5	64
13	An unexpectedly high frequency of <i>MEFV</i> mutations in patients with anti-citrullinated protein antibody-negative palindromic rheumatism. <i>Arthritis and Rheumatism</i> , 2007, 56, 2784-2788.	6.7	63
14	HLA-B27 and psoriatic disease: a modern view of an old relationship. <i>Rheumatology</i> , 2016, 55, 221-229.	1.9	56
15	Clinical Differences between Men and Women with Psoriatic Arthritis: Relevance of the Analysis of Genes and Polymorphisms in the Major Histocompatibility Complex Region and of the Age at Onset of Psoriasis. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-7.	3.3	52
16	HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2006, 8, R185.	3.5	49
17	Comprehensive Treatment of Dactylitis in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2295-2300.	2.0	45
18	Haematogenous Vertebral Osteomyelitis in the Elderly. <i>Clinical Rheumatology</i> , 2000, 19, 344-347.	2.2	44

#	ARTICLE	IF	CITATIONS
19	Obesity in psoriatic arthritis. <i>Medicine (United States)</i> , 2019, 98, e16400.	1.0	44
20	Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 355-364.	0.9	44
21	Comparative analysis of psoriatic spondyloarthropathy between men and women. <i>Rheumatology International</i> , 2001, 21, 66-68.	3.0	43
22	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B*27 Status?. <i>Arthritis Care and Research</i> , 2021, 73, 856-860.	3.4	43
23	HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis. <i>Journal of Rheumatology</i> , 2003, 30, 505-7.	2.0	41
24	Association between single nucleotide polymorphisms IL17RA rs4819554 and IL17E rs79877597 and Psoriasis in a Spanish cohort.. <i>Journal of Dermatological Science</i> , 2015, 80, 111-115.	1.9	39
25	High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). <i>Rheumatology</i> , 2011, 50, 1828-1837.	1.9	38
26	MHC class I chain-related gene B (MICB) is associated with rheumatoid arthritis susceptibility. <i>Rheumatology</i> , 2007, 46, 426-430.	1.9	35
27	RS3PE syndrome: a clinical and immunogenetical study. <i>Rheumatology International</i> , 2004, 24, 103-105.	3.0	33
28	Modelos de atención multidisciplinar en pacientes con artritis psoriásica en España. <i>Reumatología Clínica</i> , 2017, 13, 85-90.	0.5	33
29	Recomendaciones de la Sociedad Española de Reumatología sobre el tratamiento y uso de terapias sistémicas biológicas y no biológicas en artritis psoriásica. <i>Reumatología Clínica</i> , 2018, 14, 254-268.	0.5	32
30	The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients. <i>Archives of Dermatological Research</i> , 2015, 307, 405-412.	1.9	30
31	SNP rs11652075 in the <i>CARD14</i> Gene as a Risk Factor for Psoriasis (PSORS2) in a Spanish Cohort. <i>DNA and Cell Biology</i> , 2013, 32, 601-604.	1.9	29
32	The effect of HLA-DR antigens on the susceptibility to, and clinical expression of psoriatic arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2004, 33, 318-322.	1.1	27
33	Clinical expression, but not disease outcome, may vary according to age at disease onset in psoriatic spondylitis. <i>Joint Bone Spine</i> , 2008, 75, 544-547.	1.6	27
34	Common and rare <i>CARD14</i> gene variants affect the antitumour necrosis factor response among patients with psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 134-141.	1.5	27
35	Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. <i>Frontiers in Medicine</i> , 2021, 8, 679009.	2.6	27
36	Mutation analysis of the LCE3B/LCE3C genes in Psoriasis. <i>BMC Medical Genetics</i> , 2010, 11, 45.	2.1	24

#	ARTICLE	IF	CITATIONS
37	Performance of the ASAS Health Index for the Evaluation of Spondyloarthritis in Daily Practice. <i>Journal of Rheumatology</i> , 2020, 47, 1483-1489.	2.0	24
38	Association of intermittent hydrarthrosis with MEFV gene mutations. <i>Arthritis and Rheumatism</i> , 2006, 54, 2334-2335.	6.7	23
39	Enthesal ultrasound abnormalities in patients with SAPHO syndrome. <i>Clinical Rheumatology</i> , 2012, 31, 913-919.	2.2	23
40	Diferente expresión clínica de los pacientes con espondilitis anquilosante según el sexo en función del tiempo de evolución. Datos de REGISPONSER. <i>Reumatología Clínica</i> , 2013, 9, 221-225.	0.5	23
41	Age at disease onset may help to further characterize the disease phenotype in psoriatic arthritis. <i>Joint Bone Spine</i> , 2016, 83, 533-537.	1.6	23
42	Consensus Statement of the Spanish Society of Rheumatology on Risk Management of Biologic Therapy in Rheumatic Patients. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 284-298.	0.3	21
43	Patients with psoriatic arthritis may show differences in their clinical and genetic profiles depending on their age at psoriasis onset. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 476-80.	0.8	21
44	The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 313-316.	1.5	20
45	CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients. <i>International Immunopharmacology</i> , 2015, 29, 947-949.	3.8	19
46	Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 710-715.	2.0	19
47	Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study. <i>PLoS ONE</i> , 2020, 15, e0234556.	2.5	19
48	The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review. <i>Rheumatology and Therapy</i> , 2020, 7, 237-257.	2.3	19
49	A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1875-1881.	0.9	18
50	Activating killer immunoglobulin-like receptors genes are associated with increased susceptibility to ankylosing spondylitis. <i>Clinical and Experimental Immunology</i> , 2015, 180, 201-206.	2.6	18
51	Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 733-747.	1.8	18
52	Psoriatic Arthropathy after BCG Immunotherapy for Bladder Carcinoma. <i>Rheumatology</i> , 1995, 34, 1097-1097.	1.9	17
53	Standards of care for patients with spondyloarthritis. <i>Rheumatology International</i> , 2014, 34, 165-170.	3.0	17
54	Prevalence and Predictors of Cervical Involvement in Psoriatic Spondyloarthropathy. <i>Journal of Clinical Rheumatology</i> , 2002, 8, 23-29.	0.9	16

#	ARTICLE	IF	CITATIONS
55	Successful Treatment with Low-Dose Weekly Methotrexate in a Case of Undifferentiated Spondyloarthritis coexisting with Cutaneous Polyarteritis Nodosa. <i>Clinical Rheumatology</i> , 2002, 21, 304-305.	2.2	16
56	Successful therapy with low-dose colchicine in intermittent hydrarthrosis. <i>British Journal of Rheumatology</i> , 2003, 42, 391-392.	2.3	16
57	Prevalence and type II diabetes-associated factors in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 1059-1064.	2.2	16
58	Resequencing of the IL12B gene in psoriasis patients with the rs6887695/rs3212227 risk genotypes. <i>Cytokine</i> , 2012, 60, 27-29.	3.2	15
59	Dropped Head Syndrome in a Patient With Scleromyositis. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 32-34.	0.9	15
60	NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 627-633.	3.8	15
61	Construct validity of the ASAS health index in psoriatic arthritis: a cross-sectional analysis. <i>Rheumatology</i> , 2021, 60, 1465-1473.	1.9	15
62	A Single Nucleotide Polymorphism in the IL17ra Promoter Is Associated with Functional Severity of Ankylosing Spondylitis. <i>PLoS ONE</i> , 2016, 11, e0158905.	2.5	15
63	A high density SNP genotyping approach within the 19q13 chromosome region identifies an association of a CNOT3 polymorphism with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 714-717.	0.9	14
64	Erosive discovertebral lesion (Andersson lesion) as the first sign of disease in axial psoriatic arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 220-225.	1.1	14
65	Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain. <i>Rheumatology International</i> , 2018, 38, 1115-1124.	3.0	14
66	Recomendaciones para la detección, investigación y derivación del dolor lumbar inflamatorio en Atención Primaria. <i>Reumatología Clínica</i> , 2015, 11, 90-98.	0.5	13
67	Performance of Two Screening Questionnaires for Inflammatory Arthritis in Patients with Inflammatory Bowel Disease. <i>BioMed Research International</i> , 2018, 2018, 1-5.	1.9	13
68	Cardiovascular risk factors influence response to biological therapies in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 327-329.	1.2	12
69	NFKBIZ in Psoriasis: Assessing the association with gene polymorphisms and report of a new transcript variant. <i>Human Immunology</i> , 2017, 78, 435-440.	2.4	12
70	Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 381-384.	0.9	12
71	Norma de calidad para el manejo del paciente con artritis psoriásica: proyecto QUANTUM. <i>Reumatología Clínica</i> , 2020, 16, 203-215.	0.5	12
72	Association of IL1 β (-511 A/C) and IL6 (-174 G > C) polymorphisms with higher disease activity and clinical pattern of psoriatic arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 1789-1794.	2.2	11

#	ARTICLE	IF	CITATIONS
73	Expert Consensus on a Set of Outcomes to Assess the Effectiveness of Biologic Treatment in Psoriatic Arthritis: The MERECE Study. <i>Journal of Rheumatology</i> , 2020, 47, 1637-1643.	2.0	11
74	Genetic Variants of the NF- κ B Pathway: Unraveling the Genetic Architecture of Psoriatic Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13004.	4.1	11
75	HLA-DR17 is associated with enthesitis in psoriatic arthritis. <i>Joint Bone Spine</i> , 2011, 78, 428-429.	1.6	10
76	Hypertension is associated with increased age at the onset of psoriasis and a higher body mass index in psoriatic disease. <i>Clinical Rheumatology</i> , 2019, 38, 2063-2068.	2.2	10
77	Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	10
78	Multiple painful bone cysts in a young man.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 346-349.	0.9	9
79	<i>PDE3A-SLCO1C1</i> locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. <i>Pharmacogenomics</i> , 2014, 15, 1763-1769.	1.3	9
80	Multidisciplinary Care Models for Patients With Psoriatic Arthritis. <i>Reumatología Clínica (English)</i> 10 Tf 50	0.3	9
81	Polyarticular evolution and late-onset psoriasis may be associated with cardiovascular disease in psoriatic arthritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 269-274.	1.9	9
82	Remission and stringent treatment goals in psoriatic arthritis: Doctors'™ opinion is not enough. <i>Joint Bone Spine</i> , 2019, 86, 269-270.	1.6	9
83	Definition of Remission and Disease Activity Assessment in Psoriatic Arthritis: Evidence and Expert-Based Recommendations. <i>Reumatología Clínica</i> , 2021, 17, 343-350.	0.5	9
84	Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 179-188.	0.3	8
85	Stratification by age of onset with 30 years as age limit is an effective means of identifying PSORS1-associated psoriasis in patients with psoriatic arthritis. <i>Joint Bone Spine</i> , 2011, 78, 581-583.	1.6	8
86	Psoriasis and psoriasiform lesions induced by TNF α antagonists: the experience of a tertiary care hospital from northern Spain. <i>Rheumatology International</i> , 2012, 32, 3779-3783.	3.0	8
87	Multidisciplinary care for psoriatic disease. <i>Rheumatology</i> , 2017, 56, kew485.	1.9	8
88	Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?. <i>Clinical Rheumatology</i> , 2018, 37, 661-666.	2.2	8
89	Enthesitis and joint erosions are disease traits associated with cardiovascular risk in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 2973-2979.	2.2	8
90	Spectrum of psoriatic spondyloarthropathy in a cohort of 100 Spanish patients. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 857-858.	0.9	7

#	ARTICLE	IF	CITATIONS
91	Different Clinical Expression of Patients With Ankylosing Spondylitis According to Gender in Relation to Time Since Onset of Disease. Data From REGISPONER. Reumatología Clínica (English Edition), 2013, 9, 221-225.	0.3	7
92	Gene Variant in the NF- κ B Pathway Inhibitor <i>NFKBIA</i> Distinguishes Patients with Psoriatic Arthritis within the Spectrum of Psoriatic Disease. BioMed Research International, 2019, 2019, 1-6.	1.9	7
93	Registro Español de Artritis Psoriásica de Reciente Comienzo (estudio REAPSER). Objetivos y metodología. Reumatología Clínica, 2019, 15, 252-257.	0.5	7
94	Construct Validity of the Routine Assessment of Patient Index Data 3 (RAPID3) in the Evaluation of Axial Spondyloarthritis. Journal of Rheumatology, 2022, 49, 36-43.	2.0	7
95	C4 deficiency state in antiphospholipid antibody-related recurrent preeclampsia evolving into systemic lupus erythematosus. Rheumatology International, 2002, 22, 126-128.	3.0	6
96	Recommendations of the Spanish Society of Rheumatology on Treatment and Use of Systemic Biological and Non-biological Therapies in Psoriatic Arthritis. Reumatología Clínica (English Edition), 2018, 14, 254-268.	0.3	6
97	Ustekinumab in psoriatic arthritis: need for studies from real-world evidence. Expert Opinion on Biological Therapy, 2018, 18, 931-935.	3.1	6
98	Treatment-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. Arthritis Care and Research, 2020, 72, 814-821.	3.4	6
99	Improving the standard of care for patients with spondyloarthritis-related immune inflammatory conditions: results of a Delphi study and proposal for early detection. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232090429.	2.5	6
100	Evaluating standards of care in psoriatic arthritis of the QUANTUM project (qualitative initiative to) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1817-1823.	3.0	6
101	Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study. Arthritis Research and Therapy, 2020, 22, 82.	3.5	6
102	Mismatch between the impact of disease perceived by patients and the state of clinical remission assessed by physicians in psoriatic arthritis. Clinical and Experimental Rheumatology, 2020, 38, 333-336.	0.8	6
103	Ankylosing Spondylitis without Axial Progression: Analysis of Associated Factors. Journal of Rheumatology, 2014, 41, 2409-2412.	2.0	5
104	Recommendations for the Detection, Study and Referral of Inflammatory Low-back Pain in Primary Care. Reumatología Clínica (English Edition), 2015, 11, 90-98.	0.3	5
105	Recomendaciones sobre el uso de metotrexato en pacientes con artritis psoriásica. Reumatología Clínica, 2018, 14, 183-190.	0.5	5
106	Estado actual de la atención multidisciplinar para pacientes con artritis psoriásica en España: proyecto NEXUS 2.0. Reumatología Clínica, 2020, 16, 24-31.	0.5	5
107	Enfermedad de Pyle: un modelo humano de homeostasis corticotrabeccular diferenciada. Reumatología Clínica, 2020, 16, 56-58.	0.5	5
108	Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. European Journal of Clinical Nutrition, 2021, 75, 1368-1382.	2.9	5

#	ARTICLE	IF	CITATIONS
109	Potential Differences in the Cardiometabolic Risk Profile of Patients with Psoriatic Disease according to Their HLA-C<math xmlns="http://www.w3.org/1998/Math/MathML" id="M1"> <mo>^{\wedge}</mo> </math>06 Status. BioMed Research International, 2022, 2022, 1-7.	1.9	5
110	Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning. Frontiers in Medicine, 2022, 9, 891863.	2.6	5
111	The Region Centromeric to HLA-C Is a Key Region for Understanding the Phenotypic Variability of Psoriatic Arthritis. ISRN Dermatology, 2014, 2014, 1-5.	1.9	4
112	Inflammation-fatigue in spondyloarthritis: a clear link in axial spondyloarthritis but less so in psoriatic arthritis. Rheumatology, 2021, 60, 3023-3025.	1.9	4
113	Management of particular clinical situations in psoriatic arthritis: an expertâ€™s recommendation document based on systematic literature review and extended Delphi process. Rheumatology International, 2021, 41, 1549-1565.	3.0	4
114	The ASAS Health Index: A New Era for Health Impact Assessment in Spondyloarthritis. Journal of Rheumatology, 2022, 49, 8-15.	2.0	4
115	PsAID High-impact Disease in Psoriatic Arthritis: A Component Weighting Analysis of the Assessment of SpondyloArthritis international Society Health Index. Journal of Rheumatology, 2021, 48, 1886-1888.	2.0	4
116	Cardiometabolic comorbidity in the selection of treatment in spondyloarthritis: one step closer to truly personalized medicine?. Expert Opinion on Biological Therapy, 2021, 21, 1539-1541.	3.1	4
117	Analysis by Age Group of Disease Outcomes in Patients with Psoriatic Arthritis: A Cross-Sectional Multicentre Study. Drugs and Aging, 2020, 37, 99-104.	2.7	3
118	Family history of disease in spondyloarthritis: a key issue for disease prognosis. Rheumatology, 2020, 59, 2657-2658.	1.9	3
119	Analysis of the HAQ-DI components in psoriatic arthritis patients with and without low disease impact. Rheumatology, 2020, 59, 3569-3570.	1.9	3
120	Hyperlipidaemia in psoriatic disease: higher prevalence in psoriatic arthritis and inverse association with systemic therapy. Rheumatology, 2021, 60, 3949-3951.	1.9	3
121	A polyarticular onset and diabetes could be the main predictors of cardiovascular events in psoriatic arthritis. Clinical and Experimental Rheumatology, 2016, 34, 276-81.	0.8	3
122	Sexual disinterest among spondyloarthritis patients. Comparison between psoriatic arthritis and axial spondyloarthritis using a sexuality-specific question from the ASAS Health Index. Clinical and Experimental Rheumatology, 2021, 39, 922-923.	0.8	3
123	May Some Cases of Intermittent Hydrarthrosis Represent an Atypical Form of Calcium Pyrophosphate Dihydrate Crystal Deposition Disease? Usefulness of Mutational Analysis of the MEFV Gene. Seminars in Arthritis and Rheumatism, 2008, 37, 269-270.	3.4	2
124	Determinants of psoriatic arthritis in patients with psoriasis. Expert Review of Dermatology, 2010, 5, 67-77.	0.3	2
125	Quality standard for the management of patients with psoriatic arthritis: QUANTUM project. ReumatologÃa ClÃnica (English Edition), 2020, 16, 203-215.	0.3	2
126	Structural damage is not a major driver of disease impact in patients with long-standing psoriatic arthritis undergoing systemic therapy. Joint Bone Spine, 2021, 88, 105116.	1.6	2

#	ARTICLE	IF	CITATIONS
127	Propuesta de norma de certificación de calidad «SPACE» para unidades de tratamiento de pacientes con espondiloartritis axial. Reumatología Clínica, 2021, , .	0.5	2
128	Disease Activity in Psoriatic Arthritis Index and Psoriatic Arthritis Impact of Disease Questionnaire: correlation and sensitivity to change in a real clinical setting. Clinical and Experimental Rheumatology, 2020, 38, 973-977.	0.8	2
129	Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis. Clinical and Experimental Rheumatology, 0, , .	0.8	2
130	Recommendations for the Use of Methotrexate in Psoriatic Arthritis. Reumatología Clínica (English) 17(10):1073-1077. / Overlock 10 Tf	0.3	1
131	FRI0450...PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY OR REMISSION IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH APREMILAST. , 2019, , .		1
132	Ultrasound subclinical musculoskeletal findings in inflammatory bowel disease: diagnostic value of positive Doppler signal. Rheumatology, 2020, 59, 3571-3572.	1.9	1
133	ASAS Health Index as an Addition to Routine Clinical Practice. Journal of Rheumatology, 2021, 48, 787-787.	2.0	1
134	Female psoriatic arthritis: not just a matter of greater disease activity but of greater routine life impact. Clinical Rheumatology, 2021, 40, 1663-1665.	2.2	1
135	Differentiating facets of quality of life between spondyloarthritis phenotypes: added value of the ASAS health index. Rheumatology, 2021, , .	1.9	1
136	Manifestaciones atípicas de la enfermedad de Whipple. Anales De Medicina Interna, 2001, 18, .	0.1	1
137	Distribution of the components of the MDA response among patients with psoriatic arthritis with and without an acceptable symptomatic state. Clinical and Experimental Rheumatology, 2020, 38, 575-576.	0.8	1
138	Comorbilidades en las espondiloartropatías. Seminarios De La Fundación Española De Reumatología, 2010, 11, 89-93.	0.1	0
139	Ustekinumab en la artritis psoriásica y la enfermedad de Crohn. Actas Dermo-sifiliográficas, 2012, 103, 65-72.	0.4	0
140	SAT0311...Men and women with psoriatic arthritis express a different genetic profile within the major histocompatibility complex region. Annals of the Rheumatic Diseases, 2013, 71, 577.2-577.	0.9	0
141	AB0588...Prevalence of conventional cardiovascular risk factors in patients with psoriasis alone and in patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2013, 72, A969.3-A970.	0.9	0
142	FRI0556...Development of standards of care in spondyloarthritis. Annals of the Rheumatic Diseases, 2013, 72, A563.3-A563.	0.9	0
143	AB0764...An Onset of Psoriasis after 40 Years and A Low Education Level May PREDICT the Development of Diabetes Mellitus in Psoriatic Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1057.2-1057.	0.9	0
144	SAT0410...Determinants of Hypertension in Patients with Psoriatic Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 743.2-743.	0.9	0

#	ARTICLE	IF	CITATIONS
145	AB0736â€¦Strategy for the Early Detection and Referral of Patients with Suspected Spondyloarthritis: Table 1. Annals of the Rheumatic Diseases, 2014, 73, 1046.3-1047.	0.9	0
146	AB0823â€¦Age at Disease Onset Helps to Further Characterize the Disease Phenotype in Psoriatic Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1175.2-1175.	0.9	0
147	AB0824â€¦Predictors of Cerebrovascular Disease Among Psoriatic Arthritis Patients. Annals of the Rheumatic Diseases, 2015, 74, 1176.1-1176.	0.9	0
148	AB1133â€¦Epidemiological Comparative Analysis in a Large Cohort of Psoriatic Arthritis Patients: Results of the Spanish IMID Consortium. Annals of the Rheumatic Diseases, 2015, 74, 1280.3-1280.	0.9	0
149	RÃ©mission et objectifs thÃ©rapeutiques rigoureux dans le rhumatisme psoriasiqueÃ: le point de vue des mÃ©decins ne suffit pas. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 641-642.	0.0	0
150	Current status of multidisciplinary care in psoriatic arthritis in Spain: NEXUS 2.0 project. ReumatologÃa ClÃnica (English Edition), 2020, 16, 24-31.	0.3	0
151	A comparison of disease impact according to the cardiometabolic risk profile in psoriatic arthritis. Archives of Medical Science, 2021, 17, 557-560.	0.9	0
152	Definition of Remission and Disease Activity Assessment in Psoriatic Arthritis: Evidence and Expert-Based Recommendations. ReumatologÃa ClÃnica (English Edition), 2021, 17, 343-350.	0.3	0
153	PSORIASIS 696.1. , 2008, , 157-158.		0
154	Psoriatic Arthritis: A Current Vision. , 2019, , 105-105.		0
155	Quality certification standard proposal â€œSPACEâ€ for axial spondyloarthritis treatment units. ReumatologÃa ClÃnica (English Edition), 2021, , .	0.3	0
156	Disease impact in axial spondyloarthritis: Divergent roles between family history of disease and HLA-B27?. ReumatologÃa ClÃnica, 2021, , .	0.5	0
157	Good clinimetric alignment between remission and a low impact of disease in patients with axial psoriatic arthritis. Clinical and Experimental Rheumatology, 2020, 38, 136-139.	0.8	0
158	Active Disease in Psoriatic Arthritis: An Assessment of Spondyloarthritis International Society Health Index (ASAS-HI)â€¢based Analysis. Journal of Rheumatology, 0, , jrheum.210887.	2.0	0